Technology ID
TAB-3517
Small Molecule Inhibitors of LDHA for the Treatment of Glycolytic Cancers
E-Numbers
E-190-2016-0
Lead Inventor
Maloney, David (NCATS)
Co-Inventors
Mott, Bryan (NCATS)
Yang, Shyh-Ming (NCATS)
Urban, Daniel (NCATS)
Jadhav, Ajit (NCATS)
Simeonov, Anton (NCATS)
Neckers, Leonard (NCI)
Moore, William (NCI)
Waterson, Alex (Vanderbilt University)
Rai Bantukallu, Ganesha (NCATS)
Brimacombe, Kyle (NCATS)
Christov, Plamen (Vanderbilt University)
Dang, Chi (University of Pennsylvania)
Darley-Usmar, Victor (University of Alabama)
Hall, Matthew (NCATS)
Hu, Xin (NCATS)
Jana, Somnath (Vanderbilt University)
Kim, Kwangho (Vanderbilt University)
Sulikowski, Gary (Vanderbilt University)
Applications
Therapeutics
Therapeutic Areas
Oncology
Lead IC
NCATS
ICs
NCI
NCATS
This technology includes LDHA inhibitors that have been synthesized and tested for the treatment of glycolytic cancers. These compounds may have improved activity over previous compounds.
Commercial Applications
Further clinical work could establish these small molecule inhibitors of LDHA as a first-in-class/target therapy in oncology with a specific focus on glycolytic cancers.
Competitive Advantages
Currently there are no known high-quality inhibitors with demonstrated in vivo activity. These compounds are more potent than these prior art compound and have the potential for demonstrated in vivo activity as well.
Licensing Contact: